• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.

作者信息

Alachkar Nada, Bagnasco Serena M, Montgomery Robert A

出版信息

Transpl Int. 2012 Aug;25(8):e93-5. doi: 10.1111/j.1432-2277.2012.01497.x. Epub 2012 May 17.

DOI:10.1111/j.1432-2277.2012.01497.x
PMID:22591029
Abstract
摘要

相似文献

1
Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.依库珠单抗治疗肾移植中两例非典型溶血性尿毒症综合征复发
Transpl Int. 2012 Aug;25(8):e93-5. doi: 10.1111/j.1432-2277.2012.01497.x. Epub 2012 May 17.
2
Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.依库珠单抗治疗肾移植后复发性非典型溶血性尿毒症综合征的疗效
Transplantation. 2010 Apr 15;89(7):903-4. doi: 10.1097/TP.0b013e3181ccd80d.
3
Posttransplant recurrence of atypical hemolytic uremic syndrome.移植后非典型溶血尿毒综合征复发。
J Nephrol. 2012 Nov-Dec;25(6):911-7. doi: 10.5301/jn.5000146.
4
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.依库珠单抗治疗非典型溶血尿毒综合征。
N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.
5
Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.在第三次肾移植治疗伴 CFH 突变的非典型溶血尿毒症综合征后，使用依库珠单抗治疗并停止血浆置换以维持肾功能。
Am J Kidney Dis. 2010 Apr;55(4):708-11. doi: 10.1053/j.ajkd.2009.08.011. Epub 2009 Oct 25.
6
Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.依库珠单抗治疗妊娠相关非典型溶血性尿毒症综合征。
Ann Hematol. 2014 Aug;93(8):1421-2. doi: 10.1007/s00277-013-1970-3. Epub 2013 Dec 5.
7
Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.管理和预防肾移植后非典型溶血性尿毒症综合征复发。
Curr Opin Nephrol Hypertens. 2013 Nov;22(6):704-12. doi: 10.1097/MNH.0b013e328365b3fe.
8
Clinical grand rounds: atypical hemolytic uremic syndrome.临床大查房：非典型溶血尿毒综合征。
Am J Nephrol. 2012;35(5):394-400. doi: 10.1159/000337954. Epub 2012 Apr 18.
9
Eculizumab for atypical hemolytic-uremic syndrome.依库珠单抗用于非典型溶血性尿毒症综合征
N Engl J Med. 2009 Jan 29;360(5):542-4. doi: 10.1056/NEJMc0808527.
10
Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.在一名因MCP突变导致非典型溶血尿毒综合征的移植患者中，使用依库珠单抗对血栓性微血管病进行成功的长期治疗。
Transplantation. 2013 Nov 27;96(10):e74-6. doi: 10.1097/01.TP.0000435705.63428.1f.

引用本文的文献

1
The outcome of thrombotic microangiopathy in kidney transplant recipients.肾移植受者血栓性微血管病的结局。
BMC Nephrol. 2024 Nov 28;25(1):433. doi: 10.1186/s12882-024-03846-x.
2
Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.补体基因变异对依库珠单抗停药后补体介导的血栓性微血管病复发的影响。
Blood Adv. 2023 Feb 14;7(3):340-350. doi: 10.1182/bloodadvances.2021006416.
3
Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
Eculizumab 治疗非典型溶血性尿毒症综合征肾移植受者的 10 年结果：单中心经验。
BMC Nephrol. 2020 May 20;21(1):189. doi: 10.1186/s12882-020-01847-0.
4
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study.在一项长期观察性研究中，依库珠单抗可预防非典型溶血性尿毒症综合征患者的血栓性微血管病。
Clin Kidney J. 2018 May 16;12(2):196-205. doi: 10.1093/ckj/sfy035. eCollection 2019 Apr.
5
Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics.补体在血栓性微血管病中的作用：揭开补体治疗学迷宫中的阿里阿德涅之线。
Front Immunol. 2019 Feb 27;10:337. doi: 10.3389/fimmu.2019.00337. eCollection 2019.
6
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.依库珠单抗治疗非典型溶血尿毒综合征：限制使用策略。
Pediatr Nephrol. 2019 Nov;34(11):2261-2277. doi: 10.1007/s00467-018-4091-3. Epub 2018 Nov 6.
7
Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of / and the presence of CFH antibodies.在因/纯合缺失和CFH抗体存在而导致的移植后非典型溶血性尿毒症综合征中，使用贝拉西普和依库珠单抗进行有效的免疫抑制治疗。
Clin Kidney J. 2017 Dec;10(6):742-746. doi: 10.1093/ckj/sfx053. Epub 2017 Jul 10.
8
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.用于血栓性微血管病的补体C5抑制疗法：证据不断积累，但并非万灵药。
Clin Kidney J. 2017 Oct;10(5):600-624. doi: 10.1093/ckj/sfx081. Epub 2017 May 8.
9
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.关于非典型溶血性尿毒症综合征患者停用依库珠单抗的现有证据。
Clin Kidney J. 2017 Jun;10(3):310-319. doi: 10.1093/ckj/sfw115. Epub 2016 Dec 22.
10
Complement related kidney diseases: Recurrence after transplantation.补体相关肾脏疾病：移植后的复发
World J Transplant. 2016 Dec 24;6(4):632-645. doi: 10.5500/wjt.v6.i4.632.